Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / RARB

RARB

Basics

Aliases:
This biomarker is also known as:
  • retinoic acid receptor beta variant 1,
  • RAR-beta,
  • NR1B2,
  • Nuclear receptor subfamily 1 group B member 2,
  • retinoic acid receptor beta 4,
  • retinoic acid receptor beta variant 2,
  • hepatitis B virus activated protein,
  • RRB2,
  • retinoic acid receptor beta 5,
  • retinoic acid receptor, beta,
  • retinoic acid receptor, beta polypeptide,
  • HBV-activated protein,
  • retinoic acid receptor beta 2,
  • RAR-epsilon,
  • retinoic acid receptor beta,
  • HAP,

View in BioMuta

Description…

The RARB gene encodes the retinoic acid receptor beta. It is a member of the thyroid-steroid hormone receptor superfamily of nuclear transcriptional regulators (NRB1 class). These receptors bind to their targets as heterodimers in response to their ligands, all-trans or 9-cis retinoic acid, and regulate gene expression in various biological processes. This receptor localizes to the cytoplasm and to subnuclear compartments where it binds retinoic acid, the biologically active form of vitamin A which mediates cellular signalling in embryonic morphogenesis, cell growth and differentiation. It is thought that the RARB protein limits growth of many cell types by regulating gene expression. There are three distinct RAR subtypes; RARalpha, RARbeta and RARgamma. RARalpha is present in most tissue types, whereas RARbeta and RARgamma expression is more selective. Two full length transcript variants have been verified. A third is possible.

Attributes

QA State: Under Review
Type: Gene
Short Name:
HGNC Name: RARB

Datasets

There are no datasets associated with this biomarker.

Organs

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Publications

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Resources

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.